iShares NASDAQ Biotechnology Index Stock Price, News & Analysis (NASDAQ:IBB)

$110.68 +2.26 (+2.08 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$110.68
Today's Range$108.12 - $110.77
52-Week Range$94.20 - $119.30
Volume2.39 million shs
Average Volume3.25 million shs
Market Capitalization$9.84 billion
P/E Ratio3.66
Dividend Yield0.29%
Beta1.37

About iShares NASDAQ Biotechnology Index (NASDAQ:IBB)

iShares NASDAQ Biotechnology Index logoiShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund's investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc.

Receive IBB News and Ratings via Email

Sign-up to receive the latest news and ratings for IBB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Investment Trusts
Sub-IndustryN/A
SectorFinancials
SymbolNASDAQ:IBB
CUSIPN/A
Phone+1-415-5972000

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio3.6552179656539
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares87,050,000

iShares NASDAQ Biotechnology Index (NASDAQ:IBB) Frequently Asked Questions

What is iShares NASDAQ Biotechnology Index's stock symbol?

iShares NASDAQ Biotechnology Index trades on the NASDAQ under the ticker symbol "IBB."

How often does iShares NASDAQ Biotechnology Index pay dividends? What is the dividend yield for iShares NASDAQ Biotechnology Index?

iShares NASDAQ Biotechnology Index declared a quarterly dividend on Thursday, December 21st. Shareholders of record on Friday, December 22nd will be given a dividend of $0.125 per share on Thursday, December 28th. This represents a $0.50 annualized dividend and a yield of 0.45%. The ex-dividend date is Thursday, December 21st. This is a positive change from iShares NASDAQ Biotechnology Index's previous quarterly dividend of $0.04. View iShares NASDAQ Biotechnology Index's Dividend History.

When did iShares NASDAQ Biotechnology Index's stock split? How did iShares NASDAQ Biotechnology Index's stock split work?

iShares NASDAQ Biotechnology Index shares split before market open on Friday, December 1st 2017. The 3-1 split was announced on Tuesday, November 7th 2017. The newly created shares were issued to shareholders after the closing bell on Thursday, November 30th 2017. An investor that had 100 shares of iShares NASDAQ Biotechnology Index stock prior to the split would have 300 shares after the split.

Who are some of iShares NASDAQ Biotechnology Index's key competitors?

Who are iShares NASDAQ Biotechnology Index's key executives?

iShares NASDAQ Biotechnology Index's management team includes the folowing people:

  • George G. C. Parker Ph.D., Independent Chairman of the Board of Trustees (Age 78)
  • Michael Arthur Latham, President, Trustee (Age 51)
  • Jack Gee, Chief Financial Officer, Treasurer (Age 57)
  • Geoffrey D. Flynn, Chief Operating Officer, Executive Vice President
  • Amy Schioldager, Executive Vice President (Age 56)
  • Ira P. Shapiro, Vice President, Chief Legal Officer (Age 52)
  • Matt Tucker, Vice President
  • Eilleen M. Clavere, Secretary (Age 61)
  • Cecilia H. Herbert, Independent Trustee (Age 68)
  • Charles A. Hurty, Independent Trustee (Age 73)

Who owns iShares NASDAQ Biotechnology Index stock?

iShares NASDAQ Biotechnology Index's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Clal Insurance Enterprises Holdings Ltd (2.17%), CHURCHILL MANAGEMENT Corp (1.95%), Alliancebernstein L.P. (1.31%), Commerce Bank (0.90%), Meitav Dash Investments Ltd. (0.58%) and Main Management LLC (0.52%). View Institutional Ownership Trends for iShares NASDAQ Biotechnology Index.

Who sold iShares NASDAQ Biotechnology Index stock? Who is selling iShares NASDAQ Biotechnology Index stock?

iShares NASDAQ Biotechnology Index's stock was sold by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., Acropolis Investment Management LLC, Summit X LLC, K.J. Harrison & Partners Inc, Lombard Odier Asset Management Switzerland SA and Belpointe Asset Management LLC. View Insider Buying and Selling for iShares NASDAQ Biotechnology Index.

Who bought iShares NASDAQ Biotechnology Index stock? Who is buying iShares NASDAQ Biotechnology Index stock?

iShares NASDAQ Biotechnology Index's stock was bought by a variety of institutional investors in the last quarter, including Clal Insurance Enterprises Holdings Ltd, CHURCHILL MANAGEMENT Corp, Commerce Bank, Meitav Dash Investments Ltd., Alliancebernstein L.P., LPL Financial LLC, Two Sigma Advisers LP and Main Management LLC. View Insider Buying and Selling for iShares NASDAQ Biotechnology Index.

How do I buy iShares NASDAQ Biotechnology Index stock?

Shares of iShares NASDAQ Biotechnology Index can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is iShares NASDAQ Biotechnology Index's stock price today?

One share of iShares NASDAQ Biotechnology Index stock can currently be purchased for approximately $110.68.

How big of a company is iShares NASDAQ Biotechnology Index?

iShares NASDAQ Biotechnology Index has a market capitalization of $9.84 billion.

How can I contact iShares NASDAQ Biotechnology Index?

iShares NASDAQ Biotechnology Index's mailing address is 45 FREMONT STREET, SAN FRANCISCO, CA 94105, United States. The financial services provider can be reached via phone at +1-415-5972000.


MarketBeat Community Rating for iShares NASDAQ Biotechnology Index (IBB)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  60 (Vote Outperform)
Underperform Votes:  59 (Vote Underperform)
Total Votes:  119
MarketBeat's community ratings are surveys of what our community members think about iShares NASDAQ Biotechnology Index and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

iShares NASDAQ Biotechnology Index (NASDAQ:IBB) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

iShares NASDAQ Biotechnology Index (NASDAQ:IBB) Consensus Price Target History

Price Target History for iShares NASDAQ Biotechnology Index (NASDAQ:IBB)
Show:

Dividends

iShares NASDAQ Biotechnology Index (NASDAQ:IBB) Dividend Information

Most Recent Dividend:12/28/2017
Annual Dividend:$0.32
Dividend Yield:0.29%
Payout Ratio:1.06% (Trailing 12 Months of Earnings)
Dividend Payments by Quarter for iShares NASDAQ Biotechnology Index (NASDAQ:IBB)

iShares NASDAQ Biotechnology Index (NASDAQ:IBB) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
12/21/2017Quarterly$0.130.47%12/21/201712/22/201712/28/2017
9/26/2017Quarterly$0.040.14%9/26/20179/27/20179/29/2017
6/27/2017quarterly$0.060.23%6/27/20176/29/20176/30/2017
3/24/2017quarterly$0.100.41%3/24/20173/28/20173/30/2017
12/22/2016quarterly$0.030.14%12/22/201612/27/201612/29/2016
6/24/2015quarterly$0.020.06%6/24/20156/26/20156/30/2015
(Data available from 1/1/2013 forward)

Headlines

iShares NASDAQ Biotechnology Index (NASDAQ IBB) News Headlines

Source:
DateHeadline
ETF Preview: ETFs, Futures Point Lower as Fed Meeting Minutes Indicate Likelihood of More Interest Rate Hikes - NasdaqETF Preview: ETFs, Futures Point Lower as Fed Meeting Minutes Indicate Likelihood of More Interest Rate Hikes - Nasdaq
www.nasdaq.com - February 24 at 8:03 AM
Mid-Day ETF Update: ETFs, Stocks Extend Gains on Fed Speak and Pull Back in Treasury Yields - NasdaqMid-Day ETF Update: ETFs, Stocks Extend Gains on Fed Speak and Pull Back in Treasury Yields - Nasdaq
www.nasdaq.com - February 24 at 8:03 AM
Mid-Day ETF Update: ETFs, Stocks Higher as Street Shrugs Off Concerns for Possible Fed Interest Rate Hikes - NasdaqMid-Day ETF Update: ETFs, Stocks Higher as Street Shrugs Off Concerns for Possible Fed Interest Rate Hikes - Nasdaq
www.nasdaq.com - February 23 at 8:06 AM
iShares NASDAQ Biotechnology Index (IBB) versus Cannae (CNNE) Head to Head SurveyiShares NASDAQ Biotechnology Index (IBB) versus Cannae (CNNE) Head to Head Survey
www.americanbankingnews.com - February 18 at 11:08 PM
iShares NASDAQ Biotechnology Index (IBB) & Cannae (CNNE) Head-To-Head ComparisoniShares NASDAQ Biotechnology Index (IBB) & Cannae (CNNE) Head-To-Head Comparison
www.americanbankingnews.com - February 16 at 1:34 PM
3 Biotechs That Resisted The Recent Crash And Why - Seeking Alpha3 Biotechs That Resisted The Recent Crash And Why - Seeking Alpha
seekingalpha.com - February 16 at 8:07 AM
Reata Pharmaceuticals A Buy On Bardoxolene DataReata Pharmaceuticals A Buy On Bardoxolene Data
seekingalpha.com - February 14 at 3:39 PM
Mid-Day ETF Update: ETFs, Stocks Extend Gains as Trump Unveils Budget, Infrastructure Plan - NasdaqMid-Day ETF Update: ETFs, Stocks Extend Gains as Trump Unveils Budget, Infrastructure Plan - Nasdaq
www.nasdaq.com - February 12 at 3:36 PM
Teva Pharmaceutical Industries Ltd (ADR) Stock Is About to Spike - Investorplace.comTeva Pharmaceutical Industries Ltd (ADR) Stock Is About to Spike - Investorplace.com
investorplace.com - February 12 at 3:36 PM
Mid-Day ETF Update: ETFs, Stocks Resume Losses as Volatility, Concern Over Fed Hikes Eclipse Trade Data - NasdaqMid-Day ETF Update: ETFs, Stocks Resume Losses as Volatility, Concern Over Fed Hikes Eclipse Trade Data - Nasdaq
www.nasdaq.com - February 10 at 3:37 PM
Comparing Cannae (CNNE) & iShares NASDAQ Biotechnology Index (IBB)Comparing Cannae (CNNE) & iShares NASDAQ Biotechnology Index (IBB)
www.americanbankingnews.com - February 8 at 11:35 AM
A BioSci Market Outlook: How To Profit From The Coming Recession - Seeking AlphaA BioSci Market Outlook: How To Profit From The Coming Recession - Seeking Alpha
seekingalpha.com - February 8 at 8:03 AM
Spectrum Pharmaceuticals: What The Positive ADVANCE Study Entails? - Seeking AlphaSpectrum Pharmaceuticals: What The Positive ADVANCE Study Entails? - Seeking Alpha
seekingalpha.com - February 8 at 8:03 AM
Health-care sector slides 5% so far this weekHealth-care sector slides 5% so far this week
finance.yahoo.com - February 6 at 3:34 PM
Dow Gets Crushed as Bad Week Gets Worse - BarronsDow Gets Crushed as Bad Week Gets Worse - Barron's
www.barrons.com - February 4 at 8:16 AM
Array BioPharma’s Promising Drug for Colorectal CancerArray BioPharma’s Promising Drug for Colorectal Cancer
finance.yahoo.com - January 31 at 8:19 AM
In The Spotlight: IovanceIn The Spotlight: Iovance
www.nasdaq.com - January 30 at 8:11 AM
Biotech Earnings: Celgene Slides, Biogen Gains in Sector StalemateBiotech Earnings: Celgene Slides, Biogen Gains in Sector Stalemate
www.barrons.com - January 25 at 3:36 PM
Head to Head Analysis: iShares NASDAQ Biotechnology Index (IBB) and Cannae (CNNE)Head to Head Analysis: iShares NASDAQ Biotechnology Index (IBB) and Cannae (CNNE)
www.americanbankingnews.com - January 24 at 3:30 PM
A Look at Nektar Therapeutics’ Financial PerformanceA Look at Nektar Therapeutics’ Financial Performance
finance.yahoo.com - January 24 at 9:28 AM
Biotech ETFs rally to records on merger newsBiotech ETFs rally to records on merger news
www.marketwatch.com - January 22 at 3:44 PM
3 Biotech Stocks on the Verge of Major Breakouts3 Biotech Stocks on the Verge of Major Breakouts
finance.yahoo.com - January 22 at 8:15 AM
Overriding the Windfall? Why Boring Is in Biotechs Earnings FutureOverriding the Windfall? Why Boring Is in Biotech's Earnings Future
finance.yahoo.com - January 18 at 3:16 PM
Stocks Go Red As Apple, Microsoft Reverse; Bitcoin Sinks Further ... - NasdaqStocks Go Red As Apple, Microsoft Reverse; Bitcoin Sinks Further ... - Nasdaq
www.nasdaq.com - January 18 at 5:39 AM
Why Now Is the Perfect Time to Short Juno Therapeutics Inc Stock - Investorplace.comWhy Now Is the Perfect Time to Short Juno Therapeutics Inc Stock - Investorplace.com
investorplace.com - January 18 at 5:39 AM
IBB Traders Turn Defensive After Strong Run From Biotech ETFIBB Traders Turn Defensive After Strong Run From Biotech ETF
finance.yahoo.com - January 18 at 5:39 AM
Mid-Day ETF Update: ETFs, Stocks Continue Rally as Dow Clears 26,000Mid-Day ETF Update: ETFs, Stocks Continue Rally as Dow Clears 26,000
www.nasdaq.com - January 16 at 3:10 PM
Mid-Day ETF Update: ETFs, Stocks Continue to Rally On Strong Retail Sales, CPI Data and Banks Earnings - NasdaqMid-Day ETF Update: ETFs, Stocks Continue to Rally On Strong Retail Sales, CPI Data and Banks' Earnings - Nasdaq
www.nasdaq.com - January 12 at 3:12 PM
What Analysts Recommend for Insys Therapeutics and PeersWhat Analysts Recommend for Insys Therapeutics and Peers
finance.yahoo.com - January 12 at 3:12 PM
New Year, New Gilead? It’s No Longer Just About Hepatitis CNew Year, New Gilead? It’s No Longer Just About Hepatitis C
www.barrons.com - January 11 at 3:16 PM
Mid-Day ETF Update: ETFs, Stocks Turn Positive as Bond Market Jitters EaseMid-Day ETF Update: ETFs, Stocks Turn Positive as Bond Market Jitters Ease
www.nasdaq.com - January 11 at 3:15 PM
How Did Bioverativ Perform in 3Q17?How Did Bioverativ Perform in 3Q17?
finance.yahoo.com - January 11 at 5:06 AM
Mid-Day ETF Update: ETFs, Stocks Continue Slump as China Reconsiders Purchases of US Treasury Securities - NasdaqMid-Day ETF Update: ETFs, Stocks Continue Slump as China Reconsiders Purchases of US Treasury Securities - Nasdaq
www.nasdaq.com - January 10 at 3:15 PM
Trade of the Day: iShares NASDAQ Biotechnology Index (ETF) (IBB ... - Investorplace.comTrade of the Day: iShares NASDAQ Biotechnology Index (ETF) (IBB ... - Investorplace.com
investorplace.com - January 10 at 3:15 PM
Notable ETF Outflow Detected - IBB, REGN, VRTX, ILMNNotable ETF Outflow Detected - IBB, REGN, VRTX, ILMN
www.nasdaq.com - January 10 at 3:15 PM
Trade of the Day: iShares NASDAQ Biotechnology Index (ETF) (IBB)Trade of the Day: iShares NASDAQ Biotechnology Index (ETF) (IBB)
investorplace.com - January 10 at 9:40 AM
3 Ways to trade biotech3 Ways to trade biotech
finance.yahoo.com - January 10 at 5:33 AM
Exploring Mylan’s Diversified Portfolio of BrandsExploring Mylan’s Diversified Portfolio of Brands
finance.yahoo.com - January 10 at 5:33 AM
Delta, Halliburton, Intel, IBB: Fast Money Picks For January 9Delta, Halliburton, Intel, IBB: 'Fast Money' Picks For January 9
www.benzinga.com - January 9 at 3:12 PM
Indexes Bide Time Ahead Of Financial Earnings; FANGs Outperform - NasdaqIndexes Bide Time Ahead Of Financial Earnings; FANGs Outperform - Nasdaq
www.nasdaq.com - January 9 at 5:36 AM
"Fast Money" final trades: HAL, DAL and more"Fast Money" final trades: HAL, DAL and more
finance.yahoo.com - January 9 at 5:36 AM
iShares Nasdaq Biotechnology ETF Experiences Big OutflowiShares Nasdaq Biotechnology ETF Experiences Big Outflow
www.nasdaq.com - December 29 at 3:11 PM
iShares NASDAQ Biotechnology Index (IBB) to Issue Quarterly Dividend of $0.13iShares NASDAQ Biotechnology Index (IBB) to Issue Quarterly Dividend of $0.13
www.americanbankingnews.com - December 22 at 9:50 AM
In The Spotlight: Concert Pharma - Nasdaq.com - NasdaqIn The Spotlight: Concert Pharma - Nasdaq.com - Nasdaq
www.nasdaq.com - December 22 at 5:27 AM
Jonathan Faison Positions For 2018: Faster FDA Approval, Emerging Sector In China Bode Well For Biotech Next Year - Seeking AlphaJonathan Faison Positions For 2018: Faster FDA Approval, Emerging Sector In China Bode Well For Biotech Next Year - Seeking Alpha
seekingalpha.com - December 21 at 5:31 AM
Your Daily Pharma Scoop: Valeant Still Risky, Onconova Signs ... - Seeking AlphaYour Daily Pharma Scoop: Valeant Still Risky, Onconova Signs ... - Seeking Alpha
seekingalpha.com - December 21 at 5:31 AM
Biotech ETFs Can be Solid Again in 2018Biotech ETFs Can be Solid Again in 2018
www.nasdaq.com - December 20 at 3:10 PM
Top 4 ETFs to Track the Nasdaq as of December 2017Top 4 ETFs to Track the Nasdaq as of December 2017
finance.yahoo.com - December 20 at 3:10 PM
5 Biotech Stocks a Pro Is Buying - Barrons5 Biotech Stocks a Pro Is Buying - Barron's
www.barrons.com - December 20 at 5:22 AM
Why Biotech Acadia May Be Undervalued By 40%Why Biotech Acadia May Be Undervalued By 40%
finance.yahoo.com - December 19 at 3:13 PM

SEC Filings

iShares NASDAQ Biotechnology Index (NASDAQ:IBB) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

iShares NASDAQ Biotechnology Index (NASDAQ:IBB) Income Statement, Balance Sheet and Cash Flow Statement

Chart

iShares NASDAQ Biotechnology Index (NASDAQ IBB) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.